Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

RiDYMO® develops a cyclic peptide targeting the "undruggable" β-catenin in just two months

In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically "undruggable" protein, in just two months. This innovative AI-driven approach combines advanced...

NLS Pharmaceutics and Kadimastem announce a $500,000 initial closing of a $1 million fundraising, with shares priced at $3.10, a 48% premium over the January 6, 2025 market price

NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. "Kadimastem", a clinical-stage cell...

Strategic Expansion Expands Fusion Orthopedics' Foot & Ankle Reach

Fusion Orthopedics USA, LLC announced that it has expanded its robust product portfolio with the addition of the Metalogix External Fixation Systems. A seamless transition of Metalogix’s operations, distribution, and hospital accounts to Fusion is...

Eden has launched the world’s first compounded GLP-1 prescription gummy, offering a novel and convenient approach to weight management treatment

Eden has launched the world's first compounded semaglutide gummy. Designed to deliver the benefits of GLP-1 medications in a convenient, needle-free format, this innovative format reimagines how individuals approach GLP-1 programs in the United...

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

Fresenius Kabi, an operating company of Fresenius, announced that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers. Epinephrine Injection, USP is a...

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy...

MM+M honors Petauri's Nicole Lodowski as a 2025 40 Under 40 awardee

Petauri, a leading purpose-built pharmaceutical services platform, announced that Nicole Lodowski, Managing Director of Petauri Evidence, has been recognized as one of MM+M's esteemed 40 Under 40 honorees for 2025. Amanda Peterson, Vice President...

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...

UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors

UroMems, a global medical technology company developing the first smart automated implant to treat stress urinary incontinence (SUI), today announced the appointment of medical device veteran Rinda Sama to its board of directors. "We are thrilled...

Niterra Ventures invests an additional $18M in Neoplas Med GmbH, supporting advancements in innovative cancer therapies

Greifswald-based medical technology pioneer Neoplas Med GmbH is intensifying its strategic collaboration with Niterra Ventures Company, via an $18M capital increase to expand the market further for innovative wound care technology products. With a...

Automated red blood cell exchange boosts quality of life for sickle cell patients

Pain. It haunts patients with sickle cell disease (SCD). They live with the looming threat of acute pain crises that could land them in the hospital — where they can struggle to find relief. "A sickle cell disease pain crisis is indescribable. It...

Preclinical study shows NUZ-001 reduces TDP-43 aggregation in ALS

Neurizon Therapeutics Limited a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead candidate, NUZ-001. These innovative studies reveal...

HanAll Biopharma releases Q3 2024 financial results and shares business updates

HanAll Biopharma Co., Ltd. a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter of 2024 and provided business updates. HanAll ended the third...

Cure51 selects 10x Genomics Visium HD to drive its new drug discovery initiative

French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer...

GoodRx debuts a new e-commerce platform, starting with Opill®

GoodRx the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as its launch partner. This new seamless direct-to-consumer shopping experience allows consumers to order eligible...

BioCryst shares real-world data highlighting strong adherence and persistence with ORLADEYO® (berotralstat)

BioCryst Pharmaceuticals, Inc. announced new real-world comparative research on the use of oral, once-daily ORLADEYO® (berotralstat) that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with two other...

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

Clarity Pharmaceuticals a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer. Is pleased to announce it will be commencing a pivotal...

HNSA-5487 reduced IgG by over 95% in a first-in-human trial, showing redosing potential

Hansa Biopharma AB, announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing...

Promega introduces the GloMax® Galaxy Bioluminescence Imager to illuminate protein dynamics in real time

Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, today unveils the new GloMax® Galaxy Bioluminescence. The GloMax® Galaxy Bioluminescence Imager provides researchers...

Repare Therapeutics announces promising Phase 1 data showing the effectiveness of Camonsertib in combination with radiotherapy treatment

Repare Therapeutics Inc. a leading clinical-stage precision oncology company, reported data highlighting the clinical benefits of camonsertib, a potential best-in-class oral small molecule ATR inhibitor, combined with palliative radiation for the...